Database Query Results : , , FAK

FAK, FAK signaling: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
FAK (Focal Adhesion Kinase) is a non-receptor tyrosine kinase that plays a crucial role in cellular processes such as adhesion, migration, proliferation, and survival. It is primarily localized at focal adhesions, where it interacts with integrins and other signaling molecules. FAK promotes cell proliferation by activating signaling pathways such as the PI3K/Akt and MAPK/ERK pathways. These pathways are often upregulated in cancer cells, leading to uncontrolled growth.
Scientific Papers found: Click to Expand⟱
2660- AL,    Allicin: A review of its important pharmacological activities
- Review, AD, NA - Review, Var, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, AntiCan↑, *antiOx↑, *cardioP↑, *hepatoP↑, *BBB↑, *Half-Life↝, *H2S↑, *BP↓, *neuroP↑, *cognitive↑, *neuroP↑, *ROS↓, *GutMicro↑, *LDH↓, *ROS↓, *lipid-P↓, *antiOx↑, *other↑, *PI3K↓, *Akt↓, *NF-kB↓, *NO↓, *iNOS↓, *PGE2↓, *COX2↓, *IL6↓, *TNF-α↓, *MPO↓, *eff↑, *NRF2↑, *Keap1↓, *TBARS↓, *creat↓, *LDH↓, *AST↓, *ALAT↓, *MDA↓, *SOD↑, *GSH↑, *GSTs↑, *memory↑, chemoP↑, IL8↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Casp12↑, p38↑, Fas↑, P53↑, P21↑, CHK1↓, CycB/CCNB1↓, GSH↓, ROS↑, TumCCA↑, Hif1a↓, Bcl-2↓, VEGF↓, TumCMig↓, STAT3↓, VEGFR2↓, p‑FAK↓,
278- ALA,    The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment
- Review, NA, NA
ROS↑, NRF2↑, Inflam↓, frataxin↑, *BioAv↓, ChemoSen↑, Hif1a↓, eff↑, FAK↓, ITGB1↓, MMP2↓, MMP9↓, EMT↓, Snail↓, Vim↓, Zeb1↓, P53↑, MGMT↓, Mcl-1↓, Bcl-xL↓, Bcl-2↓, survivin↓, Casp3↑, Casp9↑, BAX↑, p‑Akt↓, GSK‐3β↓, *antiOx↑, *ROS↓, selectivity↑, angioG↓, MMPs↓, NF-kB↓, ITGB3↓, NADPH↓,
1123- aLinA,    Linoleic acid induces an EMT-like process in mammary epithelial cells MCF10A
- in-vitro, BC, NA - in-vitro, NA, MCF10
TumCP↑, E-cadherin↓, Snail↑, Twist↑, ZEB2↑, FAK↑, NF-kB↑, MMP2↓, MMP9↓, *EMT↑, TumCI↑,
238- Api,    Apigenin inhibits TGF-β-induced VEGF expression in human prostate carcinoma cells via a Smad2/3- and Src-dependent mechanism
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, C4-2B
VEGF↓, TGF-β↓, Src↓, FAK↓, Akt↓, SMAD2↓, SMAD3↓,
243- Api,    Apigenin Attenuates Melanoma Cell Migration by Inducing Anoikis through Integrin and Focal Adhesion Kinase Inhibition
- in-vitro, Melanoma, A375 - in-vitro, Melanoma, A2058
p‑FAK↓, ERK↓, Casp3↑, PARP↑, ITGA5↓,
273- Api,    Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase
- in-vivo, Ovarian, A2780S
FAK↓,
1547- Api,    Apigenin: Molecular Mechanisms and Therapeutic Potential against Cancer Spreading
- Review, NA, NA
angioG↓, EMT↓, CSCs↓, TumCCA↑, Dose∅, ROS↑, MMP↓, Catalase↓, GSH↓, PI3K↓, Akt↓, NF-kB↓, OCT4↓, Nanog↓, SIRT3↓, SIRT6↓, eff↑, eff↑, Cyt‑c↑, Bax:Bcl2↑, p‑GSK‐3β↓, FOXO3↑, p‑STAT3↓, MMP2↓, MMP9↓, COX2↓, MMPs↓, NRF2↓, HDAC↓, Telomerase↓, eff↑, eff↑, eff↑, eff↑, eff↑, XIAP↓, survivin↓, CK2↓, HSP90↓, Hif1a↓, FAK↓, EMT↓,
2640- Api,    Apigenin: A Promising Molecule for Cancer Prevention
- Review, Var, NA
chemoPv↑, ITGB4↓, TumCI↓, TumMeta↓, Akt↓, ERK↓, p‑JNK↓, *Inflam↓, *PKCδ↓, *MAPK↓, EGFR↓, CK2↓, TumCCA↑, CDK1↓, P53↓, P21↑, Bax:Bcl2↑, Cyt‑c↑, APAF1↑, Casp↑, cl‑PARP↑, VEGF↓, Hif1a↓, IGF-1↓, IGFBP3↑, E-cadherin↑, β-catenin/ZEB1↓, HSPs↓, Telomerase↓, FASN↓, MMPs↓, HER2/EBBR2↓, CK2↓, eff↑, AntiAg↑, eff↑, FAK↓, ROS↑, Bcl-2↓, Cyt‑c↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, cl‑IAP2↑, AR↓, PSA↓, p‑pRB↓, p‑GSK‐3β↓, CDK4↓, ChemoSen↑, Ca+2↑, cal2↑,
2639- Api,    Plant flavone apigenin: An emerging anticancer agent
- Review, Var, NA
*antiOx↑, *Inflam↓, AntiCan↑, ChemoSen↑, BioEnh↑, chemoPv↑, IL6↓, STAT3↓, NF-kB↓, IL8↓, eff↝, Akt↓, PI3K↓, HER2/EBBR2↓, cycD1/CCND1↓, CycD3↓, p27↑, FOXO3↑, STAT3↓, MMP2↓, MMP9↓, VEGF↓, Twist↓, MMP↓, ROS↑, NADPH↑, NRF2↓, SOD↓, COX2↓, p38↑, Telomerase↓, HDAC↓, HDAC1↓, HDAC3↓, Hif1a↓, angioG↓, uPA↓, Ca+2↑, Bax:Bcl2↑, Cyt‑c↑, Casp9↑, Casp12↑, Casp3↑, cl‑PARP↑, E-cadherin↑, β-catenin/ZEB1↓, cMyc↓, CDK4↓, CDK2↓, CDK6↓, IGF-1↓, CK2↓, CSCs↓, FAK↓, Gli↓, GLUT1↓,
2674- BBR,    Berberine: A novel therapeutic strategy for cancer
- Review, Var, NA - Review, IBD, NA
Inflam↓, AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumMeta↓, TumCI↓, eff↑, eff↑, CD4+↓, TNF-α↓, IL1↓, BioAv↓, BioAv↓, other↓, AMPK↑, MAPK↓, NF-kB↓, IL6↓, MCP1↓, PGE2↓, COX2↓, *ROS↓, *antiOx↑, *GPx↑, *Catalase↑, AntiTum↑, TumCP↓, angioG↓, Fas↑, FasL↑, ROS↑, ATM↑, P53↑, RB1↑, Casp9↑, Casp8↑, Casp3↓, BAX↑, Bcl-2↓, Bcl-xL↓, IAP1↓, XIAP↓, survivin↓, MMP2↓, MMP9↓, CycB/CCNB1↓, CDC25↓, CDC25↓, Cyt‑c↑, MMP↓, RenoP↑, mTOR↓, MDM2↓, LC3II↑, ERK↓, COX2↓, MMP3↓, TGF-β↓, EMT↑, ROCK1↓, FAK↓, RAS↓, Rho↓, NF-kB↓, uPA↓, MMP1↓, MMP13↓, ChemoSen↑,
2742- BetA,    Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models
- in-vitro, BC, MDA-MB-231 - in-vivo, BC, 4T1 - in-vitro, BC, MCF-7
tumCV↓, TumCMig↓, TumCI↓, STAT3↑, FAK↓, MMPs↓, MMP2↓, MMP9↓, TIMP2↑,
1517- CAP,    Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1)
- in-vitro, Bladder, TSGH8301 - in-vitro, CRC, T24
ENOX2↓, TumCCA↑, ERK↓, p‑FAK↓, p‑pax↓, TumCMig↓, EMT↓, SIRT1↓, Dose∅, ROS↑, MMP↓, Bcl-2↓, Bak↑, cl‑PARP↑, Casp3↑, SIRT1↓, ac‑P53↑, BIM↑, p‑RB1↓, cycD1/CCND1↓, Dose∅, β-catenin/ZEB1↓, N-cadherin↓, E-cadherin↑,
2781- CHr,  PBG,    Chrysin a promising anticancer agent: recent perspectives
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, MMP9↑, uPA↓, VEGF↓, AR↓, Casp↑, TumMeta↓, TumCCA↑, angioG↓, BioAv↓, *hepatoP↑, *neuroP↑, *SOD↑, *GPx↑, *ROS↓, *Inflam↓, *Catalase↑, *MDA↓, ROS↓, BBB↑, Half-Life↓, BioAv↑, ROS↑, eff↑, ROS↑, ROS↑, lipid-P↑, ER Stress↑, NOTCH1↑, NRF2↓, p‑FAK↓, Rho↓, PCNA↓, COX2↓, NF-kB↓, PDK1↓, PDK3↑, GLUT1↓, Glycolysis↓, mt-ATP↓, Ki-67↓, cMyc↓, ROCK1↓, TOP1↓, TNF-α↓, IL1β↓, CycB/CCNB1↓, CDK2↓, EMT↓, STAT3↓, PD-L1↓, IL2↑,
2805- CHr,    Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC)
- in-vitro, ESCC, KYSE150 - in-vivo, ESCC, NA
FAK↓, GlucoseCon↓, Casp3↑, Casp7↑, p‑Akt↓, TumCG↓, Weight∅,
2780- CHr,    Anti-cancer Activity of Chrysin in Cancer Therapy: a Systematic Review
- Review, Var, NA
*antiOx↑, Inflam↓, *hepatoP↑, AntiCan↑, Cyt‑c↑, Casp3↑, XIAP↓, p‑Akt↓, PI3K↑, Apoptosis↑, COX2↓, FAK↓, AMPK↑, STAT3↑, MMP↓, DNAdam↑, BAX↑, Bak↑, Casp9↑, p38↑, MAPK↑, TumCCA↑, ChemoSen↑, HDAC8↓, Wnt↓, NF-kB↓, angioG↓, BioAv↓,
2974- CUR,    Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29 - in-vitro, CRC, HCT15 - in-vitro, CRC, COLO205 - in-vitro, CRC, SW-620 - in-vivo, NA, NA
TumCMig↓, TumCI↓, TumCG↓, TumMeta↓, Sp1/3/4↓, HDAC4↓, FAK↓, CD24↓, E-cadherin↑, EMT↓, TumCP↓, NF-kB↓, AP-1↝, STAT3↓, P53?, β-catenin/ZEB1↓, NOTCH1↝, Hif1a↝, PPARα↝, Rho↓, MMP2↓, MMP9↓,
4650- CUR,    Curcumin and cancer stem cells: curcumin has asymmetrical effects on cancer and normal stem cells
- Review, Var, NA
SCD1↓, IL6↓, IL8↓, IL1↓, *selectivity↑, Wnt↝, NOTCH↝, HH↝, FAK↝,
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑, COX2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1?, PDK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,
651- EGCG,    Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications
ROS↑, p‑AMPK↑, mTOR↓, FAK↓, Smo↓, Gli1↓, HH↓, TumCMig↓, TumCI↓, NOTCH↓, JAK↓, STAT↓, Bcl-2↓, Bcl-xL↓, BAX↑, Casp9↑,
3238- EGCG,    Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications
- Review, Var, NA
Telomerase↓, DNMTs↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, HATs↓, HDAC↓, selectivity↑, uPA↓, NF-kB↓, TNF-α↓, *ROS↓, *antiOx↑, Hif1a↓, VEGF↓, MMP2↓, MMP9↓, FAK↓, TIMP2↑, Mcl-1↓, survivin↓, XIAP↓, PCNA↓, p16↑, P21↑, p27↑, pRB↑, P53↑, MDM2↑, ROS↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Diablo↑, BAX⇅, cl‑PPARα↓, PDGF↓, EGFR↓, FOXO↑, AP-1↓, JNK↓, COX2↓, angioG↓,
2830- FIS,    Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent
- Review, Var, NA
TumCG↓, angioG↓, *ROS↓, TumCMig↓, VEGF↓, MAPK↑, NF-kB↓, PI3K↓, Akt↓, mTOR↓, NRF2↑, HO-1↑, ROS↓, Inflam↓, ER Stress↑, ROS↑, TumCP↓, ChemoSen↑, PTEN↑, P53↑, Casp3↑, Casp8↑, Casp9↑, COX2↓, Wnt↓, EGFR↓, Mcl-1↓, survivin↓, IAP1↓, IAP2↓, PGE2↓, β-catenin/ZEB1↓, DR5↑, MMP2↓, MMP9↓, FAK↓, uPA↓, EMT↓, ERK↓, JNK↑, p38↑, PKCδ↓, BioAv↓, BioAv↑, BioAv↑,
830- GAR,    Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells
- in-vitro, CRC, HT-29
TumCI↓, TumCMig↓, Apoptosis↑, p‑FAK↓, Src↓, MAPK↓, ERK↓, PI3K/Akt↓, Bax:Bcl2↑, Cyt‑c↑, MMP7↓,
836- Gra,    Graviola: A Novel Promising Natural-Derived Drug That Inhibits Tumorigenicity and Metastasis of Pancreatic Cancer Cells In Vitro and In Vivo Through Altering Cell Metabolism
- vitro+vivo, PC, NA
Hif1a↓, NF-kB↓, GLUT1↓, GLUT4↓, HK2↓, LDHA↓, TumCCA↑, TumMeta↓, GlucoseCon↓, ATP↓, necrosis↑, Casp∅, p‑FAK↓, MMP9↓, MUC4↓,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
proCasp9↓, CDC2↓, CycB/CCNB1↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1/CCNA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↑, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT/TERT↓, DR5↑, Beclin-1↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
2906- LT,    Luteolin, a flavonoid with potentials for cancer prevention and therapy
- Review, Var, NA
*Inflam↓, AntiCan↑, antiOx⇅, Apoptosis↑, TumCP↓, TumMeta↓, angioG↓, PI3K↓, Akt↓, NF-kB↓, XIAP↓, P53↑, *ROS↓, *GSTA1↑, *GSR↑, *SOD↑, *Catalase↑, *other↓, ROS↑, Dose↝, chemoP↑, NF-kB↓, JNK↑, p27↑, P21↑, DR5↑, Casp↑, Fas↑, BAX↑, MAPK↓, CDK2↓, IGF-1↓, PDGF↓, EGFR↓, PKCδ↓, TOP1↓, TOP2↓, Bcl-xL↓, FASN↓, VEGF↓, VEGFR2↓, MMP9↓, Hif1a↓, FAK↓, MMP1↓, Twist↓, ERK↓, P450↓, CYP1A1↓, CYP1A2↓, TumCCA↑,
4795- Lyco,    Updates on the Anticancer Profile of Lycopene and its Probable Mechanism against Breast and Gynecological Cancer
- Review, BC, NA
TumCG↓, TumCCA↑, Apoptosis↑, P53↝, BAX↝, cycD1/CCND1↓, ERK↓, Akt↓, STAT3↓, NRF2↝, NF-kB↓, ITGB1↓, ITGA5↓, FAK↓, MMP9↓, EMT↓,
1714- Lyco,    Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load
- in-vitro, Ovarian, OV-MZ-6 - in-vivo, NA, NA
ChemoSen↑, CA125↓, ITGA5↓, ITGB1↓, MMP9↓, FAK↓, EMT↓, MAPK↓, MMP9↓, antiOx↑, Ki-67↓, MAPK↓,
3477- MF,    Electromagnetic fields regulate calcium-mediated cell fate of stem cells: osteogenesis, chondrogenesis and apoptosis
- Review, NA, NA
*Ca+2↑, *VEGF↑, *angioG↑, Ca+2↑, ROS↑, Necroptosis↑, TumCCA↑, Apoptosis↑, *ATP↑, *FAK↑, *Wnt↑, *β-catenin/ZEB1↑, *ROS↑, p38↑, MAPK↑, β-catenin/ZEB1↓, CSCs↓, TumCP↓, ROS↑, RadioS↑, Ca+2↑, eff↓, NO↑,
3535- MFrot,  MF,    Pulsed Electromagnetic Field Stimulation in Osteogenesis and Chondrogenesis: Signaling Pathways and Therapeutic Implications
- Review, Nor, NA
*eff↑, *COL2A1↑, *SOX9↑, *Ca+2↑, *FAK↑, *F-actin↑, *Inflam↓, *other↑, *Diff↑, *BMD↑,
2028- PB,    Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms
- Review, Var, NA
HDAC↓, TumCCA↑, P21↑, Dose↝, Telomerase↓, IGFBP3↑, p‑p38↑, JNK↑, ERK↑, BAX↑, Casp3↑, Bcl-2↓, Cyt‑c↝, FAK↓, survivin↓, VEGF↓, angioG↓, DNArepair↓, TumMeta↓, HSP27↑, ASK1↑, ROS↑, eff↑, ER Stress↓, GRP78/BiP↓, CHOP↑, AR↓, other?,
1661- PBG,    Propolis: a natural compound with potential as an adjuvant in cancer therapy - a review of signaling pathways
- Review, Var, NA
JNK↓, ERK↓, Akt↓, NF-kB↓, FAK↓, MAPK↓, PI3K↓, Akt↓, P21↑, p27↑, TRAIL↑, BAX↑, P53↑, ERK↓, ChemoSen↑, RadioS↑, Glycolysis↓, HK2↓, PKM2↓, LDHA↓, PFK↓,
1660- PBG,    Emerging Adjuvant Therapy for Cancer: Propolis and its Constituents
- Review, Var, NA
MMPs↓, angioG↓, TumMeta↓, TumCCA↑, Apoptosis↑, ChemoSideEff↓, eff∅, HDAC↓, PTEN↑, p‑PTEN↓, p‑Akt↓, Casp3↑, p‑ERK↑, p‑FAK↑, Dose?, Akt↓, GSK‐3β↓, FOXO3↓, eff↑, IL2↑, IL10↑, NF-kB↓, VEGF↓, mtDam↑, ER Stress↑, AST↓, ALAT↓, ALP↓, COX2↓, eff↑, Bax:Bcl2↑,
4967- PSO,    Psoralidin's Anti-Cancer Mechanisms: A Technical Guide
- Review, Var, NA
NF-kB↓, PI3K↓, Akt↓, ITGB1↓, FAK↓, BAX↑, Casp3↑, Apoptosis↑, Bcl-2↓, DR5↑, TumCCA↑, TumAuto↑, TumMeta↓,
4699- PTS,    Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, HS587T - in-vivo, BC, MDA-MB-231
TumCMig↓, TumCI↓, E-cadherin↑, Snail↓, Slug↓, Vim↓, Zeb1↑, miR-205↑, Src↓, TumCG↓, FAK↓, EMT↓,
3372- QC,  FIS,  KaempF,    Anticancer Potential of Selected Flavonols: Fisetin, Kaempferol, and Quercetin on Head and Neck Cancers
- Review, HNSCC, NA
ROCK1↑, TumCCA↓, HSPs↓, RAS↓, ROS↑, Ca+2↑, MMP↓, Cyt‑c↑, Endon↑, MMP9↓, MMP2↓, MMP7↓, MMP-10↓, VEGF↓, NF-kB↓, p65↓, iNOS↓, COX2↓, uPA↓, PI3K↓, FAK↓, MEK↓, ERK↓, JNK↓, p38↓, cJun↓, FOXO3↑,
3369- QC,    Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects
- Review, Pca, NA
FAK↓, TumCCA↑, p‑pRB↓, CDK2↑, CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt↓, ROS↑, miR-21↑, Akt↓, NF-kB↓, FasL↑, Bak↑, BAX↑, Bcl-2↓, Casp3↓, Casp9↑, P53↑, p38↑, MAPK↑, Cyt‑c↑, PARP↓, CHOP↑, ROS↓, LDH↑, GRP78/BiP↑, ERK↑, MDA↓, SOD↑, GSH↑, NRF2↑, VEGF↓, PDGF↓, EGF↓, FGF↓, TNF-α↓, TGF-β↓, VEGFR2↓, EGFR↓, FGFR1↓, mTOR↓, cMyc↓, MMPs↓, LC3B-II↑, Beclin-1↑, IL1β↓, CRP↓, IL10↓, COX2↓, IL6↓, TLR4↓, Shh↓, HER2/EBBR2↓, NOTCH↓, DR5↑, HSP70/HSPA5↓, CSCs↓, angioG↓, MMP2↓, MMP9↓, IGFBP3↑, uPA↓, uPAR↓, RAS↓, Raf↓, TSP-1↑,
3083- RES,    Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
YAP/TEAD↓, Rho↓, FAK↓, MMP9↓, ChemoSen↑, RAS↓, ROCK1↓, TumCI↓, TumMeta↓,
3081- RES,    Resveratrol and p53: How are they involved in CRC plasticity and apoptosis?
- Review, CRC, NA
NF-kB↓, FAK↓, Ki-67↓, MMP9↓, CSCs↓, CD44↓, CD133↓, ALDH1A1↓, EMT↓, ChemoSen↑, Hif1a↓, ITGB1↓, Inflam↓,
1499- SFN,    Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway
- in-vitro, BC, NA
TumCMig↓, TumCI↓, FAK↓, p‑MEK↓, p‑ERK↓,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
2197- SK,    Shikonin derivatives for cancer prevention and therapy
- Review, Var, NA
ROS↑, Ca+2↑, BAX↑, Bcl-2↓, MMP9↓, NF-kB↓, PKM2↓, Hif1a↓, NRF2↓, P53↑, DNMT1↓, MDR1↓, COX2↓, VEGF↓, EMT↓, MMP7↓, MMP13↓, uPA↓, RIP1↑, RIP3↑, Casp3↑, Casp7↑, Casp9↑, P21↓, DFF45↓, TRAIL↑, PTEN↑, mTOR↓, AR↓, FAK↓, Src↓, Myc↓, RadioS↑,
3425- TQ,    Advances in research on the relationship between thymoquinone and pancreatic cancer
Apoptosis↑, TumCP↓, TumCI↓, TumMeta↓, ChemoSen↑, angioG↓, Inflam↓, NF-kB↓, PI3K↓, Akt↓, TGF-β↓, Jun↓, p38↑, MAPK↑, MMP9↓, PKM2↓, ROS↑, JNK↑, MUC4↓, TGF-β↑, Dose↝, FAK↓, NOTCH↓, PTEN↑, mTOR↓, Warburg↓, XIAP↓, COX2↓, Casp9↑, Ki-67↓, CD34↓, VEGF↓, MCP1↓, survivin↓, Cyt‑c↑, Casp3↑, H4↑, HDAC↓,
3423- TQ,    Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics
- Review, Var, NA
AntiCan↑, Inflam↓, hepatoP↑, RenoP↑, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, ROS↑, P53↑, PTEN↑, P21↑, p27↑, BRCA1↑, PI3K↓, Akt↓, MAPK↓, ERK↓, p‑ERK↓, MMPs↓, FAK↓, Twist↓, Zeb1↓, EMT↓, TumMeta↓, angioG↓, VEGF↓, HDAC↓, Maspin↑, SIRT1↑, DNMT1↓, DNMT3A↓, HDAC1↓, HDAC4↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 45

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

chemoPv↑, 2,  

Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 1,   antiOx⇅, 1,   Catalase↓, 3,   CYP1A1↓, 2,   ENOX2↓, 1,   frataxin↑, 1,   GPx↓, 1,   GSH↓, 4,   GSH↑, 1,   GSR↓, 1,   GSTs↓, 1,   HO-1↓, 2,   HO-1↑, 1,   HO-2↓, 1,   lipid-P↑, 1,   MDA↓, 1,   NQO1↓, 1,   NRF2↓, 6,   NRF2↑, 3,   NRF2↝, 1,   ROS↓, 5,   ROS↑, 26,   SIRT3↓, 1,   SOD↓, 3,   SOD↑, 1,   SOD2↓, 1,   Trx1↑, 1,   TrxR1↓, 1,   VitC↓, 1,   VitE↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 2,   ATP↓, 2,   mt-ATP↓, 1,   CDC2↓, 1,   CDC25↓, 2,   EGF↓, 1,   FGFR1↓, 1,   MEK↓, 1,   p‑MEK↓, 1,   MMP↓, 9,   mtDam↑, 1,   Raf↓, 1,   XIAP↓, 8,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   AMPK↑, 2,   p‑AMPK↑, 1,   cMyc↓, 4,   ECAR↝, 1,   FASN↓, 2,   GlucoseCon↓, 3,   Glycolysis↓, 3,   HK2↓, 2,   lactateProd↓, 1,   LDH↑, 1,   LDHA↓, 2,   NADPH↓, 1,   NADPH↑, 1,   PDK1?, 2,   PDK1↓, 1,   PDK3↑, 1,   PFK↓, 1,   PI3K/Akt↓, 1,   PKM2↓, 4,   PPARα↝, 1,   cl‑PPARα↓, 1,   SCD1↓, 1,   SIRT1↓, 5,   SIRT1↑, 1,   SREBP1↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 17,   Akt↑, 1,   p‑Akt↓, 7,   APAF1↑, 2,   Apoptosis↑, 11,   ASK1↑, 1,   ATF2↓, 1,   Bak↑, 4,   BAX↑, 12,   BAX⇅, 1,   BAX↝, 1,   Bax:Bcl2↑, 6,   Bcl-2↓, 13,   Bcl-xL↓, 6,   BIM↑, 1,   Casp↑, 4,   Casp∅, 1,   Casp1↓, 1,   Casp12↑, 2,   Casp3↓, 2,   Casp3↑, 18,   cl‑Casp3↑, 1,   Casp7↑, 2,   cl‑Casp7↑, 1,   Casp8↑, 5,   cl‑Casp8↑, 1,   Casp9↑, 13,   cl‑Casp9↑, 1,   proCasp9↓, 1,   CK2↓, 4,   Cyt‑c↑, 16,   Cyt‑c↝, 1,   Diablo↑, 2,   DR5↑, 6,   Endon↑, 1,   Fas↑, 4,   FasL↑, 3,   GRP58↓, 1,   HGF/c-Met↓, 1,   hTERT/TERT↓, 1,   IAP1↓, 2,   IAP2↓, 1,   cl‑IAP2↑, 1,   iNOS↓, 2,   JNK↓, 3,   JNK↑, 4,   p‑JNK↓, 1,   p‑JNK↑, 2,   MAPK↓, 9,   MAPK↑, 6,   Mcl-1↓, 4,   MDM2↓, 3,   MDM2↑, 1,   p‑MDM2↓, 1,   Myc↓, 2,   Necroptosis↑, 2,   necrosis↑, 1,   NOXA↑, 1,   p27↑, 6,   p38↓, 1,   p38↑, 7,   p‑p38↑, 3,   PUMA↑, 1,   RIP1↓, 1,   RIP1↑, 1,   survivin↓, 8,   Telomerase↓, 7,   TRAIL↑, 2,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 3,   Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 1,   H3↓, 1,   H4↓, 1,   H4↑, 1,   HATs↓, 1,   HATs↑, 1,   miR-205↑, 1,   miR-21↑, 1,   other?, 1,   other↓, 1,   pRB↑, 1,   p‑pRB↓, 2,   tumCV↓, 2,  

Protein Folding & ER Stress ⓘ

CHOP↑, 3,   p‑eIF2α↑, 1,   ER Stress↓, 1,   ER Stress↑, 3,   GRP78/BiP↓, 1,   GRP78/BiP↑, 1,   HSP27↑, 1,   HSP70/HSPA5↓, 1,   HSP90↓, 1,   HSPs↓, 2,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 2,   BNIP3↑, 1,   LC3B-II↑, 1,   LC3II↑, 2,   TumAuto↑, 3,  

DNA Damage & Repair ⓘ

ATM↑, 1,   BRCA1↑, 1,   CHK1↓, 1,   DFF45↓, 1,   DNAdam↓, 1,   DNAdam↑, 1,   DNArepair↓, 1,   DNMT1↓, 2,   DNMT3A↓, 1,   DNMTs↓, 1,   MGMT↓, 1,   p16↑, 1,   P53?, 1,   P53↓, 1,   P53↑, 12,   P53↝, 1,   ac‑P53↑, 1,   PARP↓, 1,   PARP↑, 2,   cl‑PARP↑, 5,   PCNA↓, 3,   SIRT6↓, 1,   SIRT6↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 2,   CDK2↓, 7,   CDK2↑, 1,   CDK4↓, 4,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 5,   cycD1/CCND1↓, 5,   CycD3↓, 1,   cycE/CCNE↓, 2,   P21↓, 1,   P21↑, 9,   RB1↑, 1,   p‑RB1↓, 2,   TumCCA↓, 1,   TumCCA↑, 18,  

Proliferation, Differentiation & Cell State ⓘ

ALDH1A1↓, 1,   CD133↓, 1,   CD24↓, 1,   CD34↓, 2,   CD44↓, 2,   CDK8↓, 1,   cFos↑, 1,   CSCs↓, 5,   EMT↓, 17,   EMT↑, 1,   ERK↓, 13,   ERK↑, 2,   p‑ERK↓, 5,   p‑ERK↑, 1,   FGF↓, 1,   FOXO↑, 1,   FOXO3↓, 1,   FOXO3↑, 3,   Gli↓, 1,   Gli1↓, 1,   GSK‐3β↓, 2,   p‑GSK‐3β↓, 2,   HDAC↓, 9,   HDAC1↓, 2,   HDAC3↓, 1,   HDAC4↓, 2,   HDAC8↓, 1,   HH↓, 1,   HH↝, 1,   IGF-1↓, 3,   IGFBP3↑, 4,   Jun↓, 1,   mTOR↓, 9,   Nanog↓, 1,   NOTCH↓, 6,   NOTCH↝, 1,   NOTCH1↓, 1,   NOTCH1↑, 1,   NOTCH1↝, 1,   OCT4↓, 1,   PI3K↓, 13,   PI3K↑, 1,   p‑PI3K↓, 1,   PTEN↓, 1,   PTEN↑, 6,   p‑PTEN↓, 1,   RAS↓, 4,   Shh↓, 1,   Smo↓, 1,   Src↓, 5,   p‑Src↓, 1,   STAT↓, 1,   STAT3↓, 9,   STAT3↑, 2,   p‑STAT3↓, 3,   p‑STAT6↓, 1,   TOP1↓, 2,   TOP2↓, 1,   TumCG↓, 6,   Wnt↓, 4,   Wnt↝, 1,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

AntiAg↑, 1,   AP-1↓, 1,   AP-1↝, 1,   AXL↓, 1,   CA↓, 1,   Ca+2↑, 7,   Ca+2↝, 1,   cal2↑, 1,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 1,   E-cadherin↓, 2,   E-cadherin↑, 7,   FAK↓, 33,   FAK↑, 1,   FAK↝, 1,   p‑FAK↓, 7,   p‑FAK↑, 1,   ITGA5↓, 3,   ITGB1↓, 6,   ITGB3↓, 1,   ITGB4↓, 1,   Ki-67↓, 4,   MET↓, 1,   p‑MET↓, 1,   miR-203↑, 1,   MMP-10↓, 1,   MMP1↓, 2,   MMP13↓, 2,   MMP2↓, 15,   MMP3↓, 1,   MMP7↓, 3,   MMP9↓, 23,   MMP9↑, 1,   MMPs↓, 8,   MUC4↓, 2,   N-cadherin↓, 3,   p‑pax↓, 1,   PDGF↓, 4,   PKCδ↓, 3,   Rac1↓, 1,   Rho↓, 5,   RIP3↓, 1,   RIP3↑, 1,   ROCK1↓, 3,   ROCK1↑, 1,   Slug↓, 1,   SMAD2↓, 1,   SMAD3↓, 2,   Snail↓, 5,   Snail↑, 1,   TGF-β↓, 6,   TGF-β↑, 1,   TIMP2↑, 2,   TSP-1↑, 1,   TumCI↓, 10,   TumCI↑, 1,   TumCMig↓, 11,   TumCP↓, 8,   TumCP↑, 1,   TumMeta↓, 12,   Twist↓, 5,   Twist↑, 1,   Tyro3↓, 1,   uPA↓, 9,   uPAR↓, 1,   Vim↓, 4,   Vim↑, 1,   Zeb1↓, 3,   Zeb1↑, 1,   ZEB2↑, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 7,  

Angiogenesis & Vasculature ⓘ

angioG↓, 16,   EGFR↓, 7,   EGFR↑, 1,   p‑EGFR↓, 1,   Endoglin↑, 1,   Hif1a↓, 12,   Hif1a↝, 1,   NO↑, 1,   VEGF↓, 20,   VEGFR2↓, 3,  

Barriers & Transport ⓘ

BBB↑, 1,   GLUT1↓, 3,   GLUT4↓, 1,   NHE1↓, 2,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   CD4+↓, 1,   COX1↓, 1,   COX2↓, 15,   CRP↓, 1,   ICAM-1↓, 1,   IKKα↓, 1,   IL1↓, 4,   IL10↓, 1,   IL10↑, 1,   IL1β↓, 2,   IL2↑, 3,   IL6↓, 6,   IL8↓, 3,   Inflam↓, 8,   JAK↓, 2,   MCP1↓, 2,   NF-kB↓, 26,   NF-kB↑, 1,   p65↓, 1,   p‑p65↓, 1,   PD-1↓, 1,   PD-L1↓, 3,   PGE2↓, 3,   PSA↓, 2,   TLR4↓, 1,   TNF-α↓, 5,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 6,   CDK6↓, 4,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 8,   BioAv↑, 4,   BioEnh↑, 1,   ChemoSen↑, 13,   CYP1A2↓, 1,   Dose?, 1,   Dose↝, 5,   Dose∅, 4,   eff↓, 1,   eff↑, 18,   eff↝, 2,   eff∅, 1,   Half-Life↓, 2,   Half-Life↝, 1,   MDR1↓, 1,   P450↓, 1,   RadioS↑, 6,   selectivity↑, 4,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AR↓, 6,   AST↓, 1,   BRCA1↑, 1,   CA125↓, 1,   CEA↓, 1,   CRP↓, 1,   EGFR↓, 7,   EGFR↑, 1,   p‑EGFR↓, 1,   GutMicro↑, 1,   HER2/EBBR2↓, 3,   hTERT/TERT↓, 1,   IL6↓, 6,   Ki-67↓, 4,   LDH↑, 1,   Maspin↑, 1,   Myc↓, 2,   NSE↓, 1,   PD-L1↓, 3,   PSA↓, 2,  

Functional Outcomes ⓘ

AntiCan↑, 8,   AntiTum↑, 1,   cachexia↓, 1,   cardioP↑, 2,   chemoP↑, 4,   ChemoSideEff↓, 1,   hepatoP↑, 2,   RenoP↑, 2,   toxicity↝, 1,   toxicity∅, 1,   Weight∅, 1,  
Total Targets: 439

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 9,   Catalase↑, 5,   GPx↑, 3,   GSH↑, 2,   GSR↑, 2,   GSTA1↑, 1,   GSTs↑, 3,   Keap1↓, 1,   lipid-P↓, 3,   MDA↓, 2,   MPO↓, 1,   NRF2↑, 2,   ROS↓, 9,   ROS↑, 1,   SOD↑, 5,   TBARS↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 1,   MMP↑, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   H2S↑, 1,   LDH↓, 2,   SIRT1↑, 1,  

Cell Death ⓘ

Akt↓, 1,   Casp3↓, 1,   iNOS↓, 1,   MAPK↓, 1,  

Kinase & Signal Transduction ⓘ

SOX9↑, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,   other↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

Diff↑, 1,   EMT↑, 1,   PI3K↓, 1,   Wnt↑, 1,  

Migration ⓘ

Ca+2↑, 2,   COL2A1↑, 1,   F-actin↑, 1,   FAK↑, 2,   PKCδ↓, 1,   TIMP1↓, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↑, 1,   NO↓, 2,   VEGF↑, 1,  

Barriers & Transport ⓘ

BBB↑, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL10↑, 1,   IL1β↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 7,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   eff↑, 3,   Half-Life↝, 2,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   BMD↑, 1,   BP↓, 1,   creat↓, 1,   GutMicro↑, 1,   IL6↓, 1,   LDH↓, 2,  

Functional Outcomes ⓘ

cardioP↑, 1,   cognitive↑, 1,   hepatoP↑, 3,   memory↑, 1,   neuroP↑, 4,  
Total Targets: 72

Scientific Paper Hit Count for: FAK, FAK signaling
6 Apigenin (mainly Parsley)
3 Chrysin
3 Propolis -bee glue
3 Luteolin
2 Curcumin
2 EGCG (Epigallocatechin Gallate)
2 Fisetin
2 Lycopene
2 Magnetic Fields
2 Quercetin
2 Resveratrol
2 Shikonin
2 Thymoquinone
1 Allicin (mainly Garlic)
1 Alpha-Lipoic-Acid
1 alpha Linolenic acid
1 Berberine
1 Betulinic acid
1 Capsaicin
1 Ellagic acid
1 Garcinol
1 Graviola
1 Magnetic Field Rotating
1 Phenylbutyrate
1 Psoralidin
1 Pterostilbene
1 Kaempferol
1 Sulforaphane (mainly Broccoli)
1 Silymarin (Milk Thistle) silibinin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:110  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page